FluoroPharma Medical, Inc. engages in the discovery, development, and commercialization of proprietary medical diagnostic imaging products. The company is headquartered in Montclair, New Jersey and currently employs 4 full-time employees. The company went IPO on 2008-08-18. The firm is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). BFPET program employs a (18F)-labeled cationic lipophilic tetraphenylphosphonium ion as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. The company measures the extent and severity of cardiovascular disease through the detection of ischemic and infarcted myocardial tissue. CardioPET program employs Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
Follow-Up Questions
FluoroPharma Medical Inc (FPMI)의 PER은 얼마입니까?
FluoroPharma Medical Inc의 PER은 0입니다
FluoroPharma Medical Inc의 CEO는 누구입니까?
Dr. Thomas Tulip은 2015부터 회사에 합류한 FluoroPharma Medical Inc의 Chief Executive Officer입니다.
FPMI 주식의 가격 성능은 어떻습니까?
FPMI의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
FluoroPharma Medical Inc의 주요 사업 주제나 업종은 무엇입니까?
FluoroPharma Medical Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
